Postmarketing analysis of aflibercept-related sterile intraocular inflammation

Paul Hahn, Mina M. Chung, Harry W Flynn, Suber S. Huang, Judy E. Kim, Tamer H. Mahmoud, Srinivas R. Sadda, Pravin U. Dugel

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

IMPORTANCE: Aflibercept-related sterile inflammation, an event that is poorly understood, has been the subject of ongoing postmarketing reports. OBJECTIVE: To analyze cases of aflibercept-related sterile inflammation reported to the American Society of Retina Specialists (ASRS) Therapeutic Surveillance Committee (TSC), an independent task force formed to monitor drug- and device-related safety events. DESIGN, SETTING, AND PARTICIPANTS: A retrospective review of 56 cases in 55 patients was performed of all cases of sterile inflammation after aflibercept injection that were voluntarily reported by 12 practices throughout the United States to the ASRS TSC from December 1, 2011, through February 12, 2014. MAINOUTCOMESAND MEASURES: Cases of aflibercept-related sterile inflammation were analyzed for baseline and demographic information, presenting symptoms and findings, visual acuity changes, injection technique, and management details. RESULTS: Among 56 reported cases of sterile inflammation, mean time to onset was 3.5 days (median, 2 days; range, 0-30 days). Most cases consisted of initial loss of vision and intraocular inflammation without prominent redness, severe pain, or hypopyon. Thirty-seven cases (66%) were treated with topical corticosteroids and/or observation alone. Mean time to resolution was 28.6 days (median, 28 days; range, 4-84 days). Although final vision was overall unchanged, some patients developed permanent vision loss, which may have resulted from inflammation and/or progression of the underlying disease. Age older than 80 years was associated with worse visual outcomes. No difference in visual outcome was detected in patients with sterile inflammation undergoing topical therapy alone vs invasive procedures (vitreous biopsy and/or intravitreal antibiotic administration and/or vitrectomy). CONCLUSIONS AND RELEVANCE: With the largest number of reported cases of aflibercept-related sterile inflammation to our knowledge, this analysis suggests typical findings and an often favorable prognosis of this event. Analysis of real-world, postmarketing data has limitations, and these findings should be considered as hypothesis-generating assessments rather than a definitive reflection of this event or its typical course. Distinguishing sterile inflammation and infectious endophthalmitis at the time of presentation may often be difficult, and cautious evaluation and management of these patients are warranted. The ASRS TSC encourages active postmarketing surveillance by all physicians.

Original languageEnglish (US)
Pages (from-to)421-426
Number of pages6
JournalJAMA Ophthalmology
Volume133
Issue number4
DOIs
StatePublished - Apr 1 2015

Fingerprint

Inflammation
Pharmacy and Therapeutics Committee
Retina
aflibercept
Equipment Safety
Injections
Endophthalmitis
Vitrectomy
Advisory Committees
Visual Acuity
Disease Progression
Adrenal Cortex Hormones
Observation
Demography
Anti-Bacterial Agents
Physicians
Biopsy
Pain
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Hahn, P., Chung, M. M., Flynn, H. W., Huang, S. S., Kim, J. E., Mahmoud, T. H., ... Dugel, P. U. (2015). Postmarketing analysis of aflibercept-related sterile intraocular inflammation. JAMA Ophthalmology, 133(4), 421-426. https://doi.org/10.1001/jamaophthalmol.2014.5650

Postmarketing analysis of aflibercept-related sterile intraocular inflammation. / Hahn, Paul; Chung, Mina M.; Flynn, Harry W; Huang, Suber S.; Kim, Judy E.; Mahmoud, Tamer H.; Sadda, Srinivas R.; Dugel, Pravin U.

In: JAMA Ophthalmology, Vol. 133, No. 4, 01.04.2015, p. 421-426.

Research output: Contribution to journalArticle

Hahn, P, Chung, MM, Flynn, HW, Huang, SS, Kim, JE, Mahmoud, TH, Sadda, SR & Dugel, PU 2015, 'Postmarketing analysis of aflibercept-related sterile intraocular inflammation', JAMA Ophthalmology, vol. 133, no. 4, pp. 421-426. https://doi.org/10.1001/jamaophthalmol.2014.5650
Hahn, Paul ; Chung, Mina M. ; Flynn, Harry W ; Huang, Suber S. ; Kim, Judy E. ; Mahmoud, Tamer H. ; Sadda, Srinivas R. ; Dugel, Pravin U. / Postmarketing analysis of aflibercept-related sterile intraocular inflammation. In: JAMA Ophthalmology. 2015 ; Vol. 133, No. 4. pp. 421-426.
@article{d897684bb38f4a38b83c248fed05a79a,
title = "Postmarketing analysis of aflibercept-related sterile intraocular inflammation",
abstract = "IMPORTANCE: Aflibercept-related sterile inflammation, an event that is poorly understood, has been the subject of ongoing postmarketing reports. OBJECTIVE: To analyze cases of aflibercept-related sterile inflammation reported to the American Society of Retina Specialists (ASRS) Therapeutic Surveillance Committee (TSC), an independent task force formed to monitor drug- and device-related safety events. DESIGN, SETTING, AND PARTICIPANTS: A retrospective review of 56 cases in 55 patients was performed of all cases of sterile inflammation after aflibercept injection that were voluntarily reported by 12 practices throughout the United States to the ASRS TSC from December 1, 2011, through February 12, 2014. MAINOUTCOMESAND MEASURES: Cases of aflibercept-related sterile inflammation were analyzed for baseline and demographic information, presenting symptoms and findings, visual acuity changes, injection technique, and management details. RESULTS: Among 56 reported cases of sterile inflammation, mean time to onset was 3.5 days (median, 2 days; range, 0-30 days). Most cases consisted of initial loss of vision and intraocular inflammation without prominent redness, severe pain, or hypopyon. Thirty-seven cases (66{\%}) were treated with topical corticosteroids and/or observation alone. Mean time to resolution was 28.6 days (median, 28 days; range, 4-84 days). Although final vision was overall unchanged, some patients developed permanent vision loss, which may have resulted from inflammation and/or progression of the underlying disease. Age older than 80 years was associated with worse visual outcomes. No difference in visual outcome was detected in patients with sterile inflammation undergoing topical therapy alone vs invasive procedures (vitreous biopsy and/or intravitreal antibiotic administration and/or vitrectomy). CONCLUSIONS AND RELEVANCE: With the largest number of reported cases of aflibercept-related sterile inflammation to our knowledge, this analysis suggests typical findings and an often favorable prognosis of this event. Analysis of real-world, postmarketing data has limitations, and these findings should be considered as hypothesis-generating assessments rather than a definitive reflection of this event or its typical course. Distinguishing sterile inflammation and infectious endophthalmitis at the time of presentation may often be difficult, and cautious evaluation and management of these patients are warranted. The ASRS TSC encourages active postmarketing surveillance by all physicians.",
author = "Paul Hahn and Chung, {Mina M.} and Flynn, {Harry W} and Huang, {Suber S.} and Kim, {Judy E.} and Mahmoud, {Tamer H.} and Sadda, {Srinivas R.} and Dugel, {Pravin U.}",
year = "2015",
month = "4",
day = "1",
doi = "10.1001/jamaophthalmol.2014.5650",
language = "English (US)",
volume = "133",
pages = "421--426",
journal = "JAMA Ophthalmology",
issn = "2168-6165",
publisher = "American Medical Association",
number = "4",

}

TY - JOUR

T1 - Postmarketing analysis of aflibercept-related sterile intraocular inflammation

AU - Hahn, Paul

AU - Chung, Mina M.

AU - Flynn, Harry W

AU - Huang, Suber S.

AU - Kim, Judy E.

AU - Mahmoud, Tamer H.

AU - Sadda, Srinivas R.

AU - Dugel, Pravin U.

PY - 2015/4/1

Y1 - 2015/4/1

N2 - IMPORTANCE: Aflibercept-related sterile inflammation, an event that is poorly understood, has been the subject of ongoing postmarketing reports. OBJECTIVE: To analyze cases of aflibercept-related sterile inflammation reported to the American Society of Retina Specialists (ASRS) Therapeutic Surveillance Committee (TSC), an independent task force formed to monitor drug- and device-related safety events. DESIGN, SETTING, AND PARTICIPANTS: A retrospective review of 56 cases in 55 patients was performed of all cases of sterile inflammation after aflibercept injection that were voluntarily reported by 12 practices throughout the United States to the ASRS TSC from December 1, 2011, through February 12, 2014. MAINOUTCOMESAND MEASURES: Cases of aflibercept-related sterile inflammation were analyzed for baseline and demographic information, presenting symptoms and findings, visual acuity changes, injection technique, and management details. RESULTS: Among 56 reported cases of sterile inflammation, mean time to onset was 3.5 days (median, 2 days; range, 0-30 days). Most cases consisted of initial loss of vision and intraocular inflammation without prominent redness, severe pain, or hypopyon. Thirty-seven cases (66%) were treated with topical corticosteroids and/or observation alone. Mean time to resolution was 28.6 days (median, 28 days; range, 4-84 days). Although final vision was overall unchanged, some patients developed permanent vision loss, which may have resulted from inflammation and/or progression of the underlying disease. Age older than 80 years was associated with worse visual outcomes. No difference in visual outcome was detected in patients with sterile inflammation undergoing topical therapy alone vs invasive procedures (vitreous biopsy and/or intravitreal antibiotic administration and/or vitrectomy). CONCLUSIONS AND RELEVANCE: With the largest number of reported cases of aflibercept-related sterile inflammation to our knowledge, this analysis suggests typical findings and an often favorable prognosis of this event. Analysis of real-world, postmarketing data has limitations, and these findings should be considered as hypothesis-generating assessments rather than a definitive reflection of this event or its typical course. Distinguishing sterile inflammation and infectious endophthalmitis at the time of presentation may often be difficult, and cautious evaluation and management of these patients are warranted. The ASRS TSC encourages active postmarketing surveillance by all physicians.

AB - IMPORTANCE: Aflibercept-related sterile inflammation, an event that is poorly understood, has been the subject of ongoing postmarketing reports. OBJECTIVE: To analyze cases of aflibercept-related sterile inflammation reported to the American Society of Retina Specialists (ASRS) Therapeutic Surveillance Committee (TSC), an independent task force formed to monitor drug- and device-related safety events. DESIGN, SETTING, AND PARTICIPANTS: A retrospective review of 56 cases in 55 patients was performed of all cases of sterile inflammation after aflibercept injection that were voluntarily reported by 12 practices throughout the United States to the ASRS TSC from December 1, 2011, through February 12, 2014. MAINOUTCOMESAND MEASURES: Cases of aflibercept-related sterile inflammation were analyzed for baseline and demographic information, presenting symptoms and findings, visual acuity changes, injection technique, and management details. RESULTS: Among 56 reported cases of sterile inflammation, mean time to onset was 3.5 days (median, 2 days; range, 0-30 days). Most cases consisted of initial loss of vision and intraocular inflammation without prominent redness, severe pain, or hypopyon. Thirty-seven cases (66%) were treated with topical corticosteroids and/or observation alone. Mean time to resolution was 28.6 days (median, 28 days; range, 4-84 days). Although final vision was overall unchanged, some patients developed permanent vision loss, which may have resulted from inflammation and/or progression of the underlying disease. Age older than 80 years was associated with worse visual outcomes. No difference in visual outcome was detected in patients with sterile inflammation undergoing topical therapy alone vs invasive procedures (vitreous biopsy and/or intravitreal antibiotic administration and/or vitrectomy). CONCLUSIONS AND RELEVANCE: With the largest number of reported cases of aflibercept-related sterile inflammation to our knowledge, this analysis suggests typical findings and an often favorable prognosis of this event. Analysis of real-world, postmarketing data has limitations, and these findings should be considered as hypothesis-generating assessments rather than a definitive reflection of this event or its typical course. Distinguishing sterile inflammation and infectious endophthalmitis at the time of presentation may often be difficult, and cautious evaluation and management of these patients are warranted. The ASRS TSC encourages active postmarketing surveillance by all physicians.

UR - http://www.scopus.com/inward/record.url?scp=84928252920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928252920&partnerID=8YFLogxK

U2 - 10.1001/jamaophthalmol.2014.5650

DO - 10.1001/jamaophthalmol.2014.5650

M3 - Article

VL - 133

SP - 421

EP - 426

JO - JAMA Ophthalmology

JF - JAMA Ophthalmology

SN - 2168-6165

IS - 4

ER -